European journal of neurology · 2020
Cross-sectional and longitudinal associations between probable rapid eye movement sleep behavior disorder and impulse control disorders in Parkinson's disease.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cao R, Chen X, Xing F, Xie C, Hu P, Wang K
Аннотация
BACKGROUND AND PURPOSE: The aim was to investigate whether probable rapid eye movement sleep behavior disorder (pRBD) is associated with impulse control disorders (ICDs) in drug-naïve patients with Parkinson's disease (PD) and whether baseline pRBD is associated with a higher incidence of ICDs during follow-up.
METHODS: The Parkinson's Progression Markers Initiative is an international, multicenter, prospective cohort study to identify biomarkers of PD progression. In all, 423 drug-naïve patients with early-stage PD were included in the cross-sectional analysis, and 320 patients who screened negative for any ICDs or related behaviors at baseline were included in the longitudinal analysis.
RESULTS: In the cross-sectional analysis, a significant correlation was found between pRBD and ICDs in drug-naïve patients whilst controlling for potential confounders [odds ratio 2.56, 95% confidence interval (CI) 1.38-4.76, P = 0.003]. In the longitudinal analysis, baseline pRBD was an independent predictor of ICD development over time [hazard ratio (HR) 1.648, 95% CI 1.054-2.576; P = 0.028]. Other significant predictors of ICDs included younger age of onset (HR = 0.973, 95% CI = 0.950-0.997; P = 0.026) and greater State-Trait Anxiety Inventory score (HR = 1.040, 95% CI = 1.020-1.061; P < 0.001).
CONCLUSION: Our data suggest that identifying baseline pRBD in early-stage PD may help clinicians to choose a better therapeutic strategy so as to prevent or limit neuropsychiatric complications.
METHODS: The Parkinson's Progression Markers Initiative is an international, multicenter, prospective cohort study to identify biomarkers of PD progression. In all, 423 drug-naïve patients with early-stage PD were included in the cross-sectional analysis, and 320 patients who screened negative for any ICDs or related behaviors at baseline were included in the longitudinal analysis.
RESULTS: In the cross-sectional analysis, a significant correlation was found between pRBD and ICDs in drug-naïve patients whilst controlling for potential confounders [odds ratio 2.56, 95% confidence interval (CI) 1.38-4.76, P = 0.003]. In the longitudinal analysis, baseline pRBD was an independent predictor of ICD development over time [hazard ratio (HR) 1.648, 95% CI 1.054-2.576; P = 0.028]. Other significant predictors of ICDs included younger age of onset (HR = 0.973, 95% CI = 0.950-0.997; P = 0.026) and greater State-Trait Anxiety Inventory score (HR = 1.040, 95% CI = 1.020-1.061; P < 0.001).
CONCLUSION: Our data suggest that identifying baseline pRBD in early-stage PD may help clinicians to choose a better therapeutic strategy so as to prevent or limit neuropsychiatric complications.